Quick Answer: No
Given the widespread use of GLP1 agents and ongoing safety concerns, future research needs to study these drugs in breast cancer patients, critically evaluating their impact on cancer risk, recurrence, mortality, and longterm outcomes for this population
This is not a rejection of GLP-1s
At its core is a surge of fake ads promoting fake miracle health products for chronic conditions: GLP-1 weight-loss alternatives, arthritis creams, bronchitis inhalers, glaucoma drops, and more
These changes translate to meaningful cardiovascular risk reduction
(1) It is an epidemic that has increased Americans risk of weight-related health issues, such as heart disease, type 2 diabetes, high blood pressure, reduced quality of life, and more